Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion.

In this review, the clinical pharmacology of high-dose doxorubicin is examined, and the pharmacokinetics of infusional doxorubicin at standard and high dose are compared. The data developed here, including recent clinical trials of high-dose infusional doxorubicin, demonstrate the safety and efficacy of doxorubicin administration at doses > or = 150 mg/m2 for patients with breast cancer and strongly suggest that the utility of this drug can be substantially increased with appropriate hematopoietic support.
AuthorsT W Synold, J H Doroshow
JournalThe Journal of infusional chemotherapy (J Infus Chemother) Vol. 6 Issue 2 Pg. 69-73 ( 1996) ISSN: 1060-0051 [Print] UNITED STATES
PMID8809652 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Review)
Chemical References
  • Antibiotics, Antineoplastic
  • Doxorubicin
  • Antibiotics, Antineoplastic (administration & dosage, pharmacokinetics)
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Doxorubicin (administration & dosage, pharmacokinetics)
  • Drug Administration Schedule
  • Humans
  • Infusions, Intravenous
  • Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password:
Type Validation Code Shown: